{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:15:56Z","timestamp":1783332956155,"version":"3.54.6"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00790-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:00:59Z","timestamp":1781265659000},"page":"693-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2048-2154","authenticated-orcid":false,"given":"Capucine","family":"Arriv\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hotot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Jourdil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"3","key":"790_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"790_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FTD.0000000000001250","volume":"47","author":"S Masuda","year":"2025","unstructured":"Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, et al. Everolimus personalized therapy: Second consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2025;47(1):4\u201331. https:\/\/doi.org\/10.1097\/FTD.0000000000001250.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"790_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1034\/j.1399-0012.2000.140201.x","volume":"14","author":"BD Kahan","year":"2000","unstructured":"Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant. 2000;14(2):97\u2013109. https:\/\/doi.org\/10.1034\/j.1399-0012.2000.140201.x.","journal-title":"Clin Transplant"},{"issue":"1","key":"790_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/FTD.0000000000000364","volume":"39","author":"JE Ericson","year":"2017","unstructured":"Ericson JE, Zimmerman KO, Gonzalez D, Melloni C, Guptill JT, Hill KD, et al. A systematic literature review approach to estimate the therapeutic index of selected immunosuppressant drugs after renal transplantation. Ther Drug Monit. 2017;39(1):13\u201320. https:\/\/doi.org\/10.1097\/FTD.0000000000000364.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"790_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: Consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150\u2013200. https:\/\/doi.org\/10.1097\/FTD.0000000000000871.","journal-title":"Ther Drug Monit"},{"key":"790_CR6","first-page":"333","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN. Variability. In: Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2011. p. 333\u201355.","edition":"4th ed"},{"issue":"11","key":"790_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00228-014-1740-8","volume":"70","author":"HS Al-Sallami","year":"2014","unstructured":"Al-Sallami HS, Cheah SL, Han SY, Liew J, Lim J, Ng MA, et al. Between-subject variability: should high be the new normal? Eur J Clin Pharmacol. 2014;70(11):1403\u20134. https:\/\/doi.org\/10.1007\/s00228-014-1740-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"790_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12662","volume":"35","author":"A Truffot","year":"2021","unstructured":"Truffot A, Gautier-Veyret E, Baillet A, Jourdil JF, Stanke-Labesque F, Gottenberg JE. Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundam Clin Pharmacol. 2021;35(6):6. https:\/\/doi.org\/10.1111\/fcp.12662.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"790_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40259-024-00676-z","volume":"38","author":"C Arriv\u00e9","year":"2024","unstructured":"Arriv\u00e9 C, Bazzoli C, Jouve T, Noble J, Rostaing L, Stanke-Labesque F, et al. A population pharmacokinetic model of tocilizumab in kidney transplant patients treated for chronic active antibody-mediated rejection: comparison of plasma exposure between intravenous and subcutaneous administration schemes. BioDrugs. 2024;38(5):703\u201316. https:\/\/doi.org\/10.1007\/s40259-024-00676-z.","journal-title":"BioDrugs"},{"key":"790_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.610806","volume":"11","author":"A Di Paolo","year":"2020","unstructured":"Di Paolo A, Luci G. Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond. Front Pharmacol. 2020;11:610806. https:\/\/doi.org\/10.3389\/fphar.2020.610806.","journal-title":"Front Pharmacol"},{"issue":"23","key":"790_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, Brun MK, Sandanger \u00d8, Bj\u00f8rlykke KH, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384. https:\/\/doi.org\/10.1001\/jama.2021.21316.","journal-title":"JAMA"},{"issue":"6","key":"790_CR12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/bcp.16170","volume":"91","author":"S Bergan","year":"2025","unstructured":"Bergan S, Vethe NT. The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation. Br J Clin Pharmacol. 2025;91(6):1542\u201350. https:\/\/doi.org\/10.1111\/bcp.16170.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"790_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/00007890-199911150-00012","volume":"68","author":"JM Kovarik","year":"1999","unstructured":"Kovarik JM, Kahan BD, Rajagopalan PR, Bennett W, Mulloy LL, Gerbeau C, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation: the US Simulect Renal Transplant Study Group. Transplantation. 1999;68(9):1288\u201394. https:\/\/doi.org\/10.1097\/00007890-199911150-00012.","journal-title":"Transplantation"},{"key":"790_CR14","unstructured":"European Medicines Agency. Nulojix: summary of product characteristics. Amsterdam: European Medicines Agency; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nulojix-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR15","unstructured":"European Medicines Agency. RoActemra: EPAR: product information. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR16","unstructured":"European Medicines Agency. Simulect (basiliximab): summary of product characteristics. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simulect-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR17","unstructured":"European Medicines Agency. Mabthera (rituximab): Summary of product characteristics. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"issue":"6","key":"790_CR18","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1097\/FTD.0000000000001353","volume":"47","author":"M Larrosa-Garc\u00eda","year":"2025","unstructured":"Larrosa-Garc\u00eda M, Agraz Pamplona I, Sanz Mart\u00ednez MT, Bury Mac\u00edas RP, Mart\u00ednez Gallo M, Colobran R, et al. Pharmacokinetic characterization of rituximab in patients with glomerular diseases. Ther Drug Monit. 2025;47(6):e142\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000001353.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"790_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.2600.8","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Fo\u00e0 R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5(6):826\u201337. https:\/\/doi.org\/10.4161\/mabs.2600.8.","journal-title":"MAbs"},{"issue":"4","key":"790_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/bcp.15608","volume":"89","author":"TC Zwart","year":"2023","unstructured":"Zwart TC, Bezstarosti S, Achini FR, Reinders MEJ, Schilham MW, Heidt S, et al. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. Br J Clin Pharmacol. 2023;89(4):1471\u201385. https:\/\/doi.org\/10.1111\/bcp.15608.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"790_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","volume":"57","author":"M van der Zwan","year":"2018","unstructured":"van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet. 2018;57(2):191\u2013207. https:\/\/doi.org\/10.1007\/s40262-017-0573-x.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"790_CR22","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/ckj\/sfab049","volume":"14","author":"H Boulay","year":"2021","unstructured":"Boulay H, Mazaud-Guittot S, Supervielle J, Chemouny JM, Dardier V, Lacroix A, et al. Maternal, foetal and child consequences of immunosuppressive drugs during pregnancy in women with organ transplant: a review. Clin Kidney J. 2021;14(8):1871\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfab049.","journal-title":"Clin Kidney J"},{"issue":"2","key":"790_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/clpt.2012.84","volume":"92","author":"Z Zhou","year":"2012","unstructured":"Zhou Z, Shen J, Hong Y, Kaul S, Pfister M, Roy A. Time-varying belatacept exposure and its relationship to efficacy\/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92(2):251\u20137. https:\/\/doi.org\/10.1038\/clpt.2012.84.","journal-title":"Clin Pharmacol Ther"},{"key":"790_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R, French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107627.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"790_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14853","volume":"37","author":"P Khairallah","year":"2023","unstructured":"Khairallah P, Robbins-Juarez S, Patel S, Shah V, Toma K, Fernandez H, et al. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients. Clin Transplant. 2023;37(1):e14853. https:\/\/doi.org\/10.1111\/ctr.14853.","journal-title":"Clin Transplant"},{"issue":"22","key":"790_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227141","volume":"12","author":"C Arriv\u00e9","year":"2023","unstructured":"Arriv\u00e9 C, Jacquet M, Gautier-Veyret E, Jouve T, Noble J, Lombardo D, et al. Early exposure of kidney transplant recipients with chronic antibody-mediated rejection to tocilizumab: a preliminary study. J Clin Med. 2023;12(22):7141. https:\/\/doi.org\/10.3390\/jcm12227141.","journal-title":"J Clin Med"},{"issue":"9","key":"790_CR27","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259\u201366. https:\/\/doi.org\/10.1681\/ASN.2014080799.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"790_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jcph.1545","volume":"60","author":"G An","year":"2020","unstructured":"An G. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 2020;60(2):149\u201363. https:\/\/doi.org\/10.1002\/jcph.1545.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"790_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ekir.2023.10.023","volume":"9","author":"A Destere","year":"2024","unstructured":"Destere A, Teisseyre M, Merino D, Cremoni M, G\u00e9rard AO, Crepin T, et al. Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence. Kidney Int Rep. 2024;9(1):134\u201344. https:\/\/doi.org\/10.1016\/j.ekir.2023.10.023.","journal-title":"Kidney Int Rep."},{"key":"790_CR30","unstructured":"European Medicines Agency. Lemtrada: EPAR: product information. Amsterdam: European Medicines Agency; 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR31","unstructured":"European Medicines Agency. Soliris: EPAR: product information. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR32","unstructured":"European Medicines Agency. Ultomiris: summary of product characteristics. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"issue":"2","key":"790_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40261-013-0153-2","volume":"34","author":"J Shen","year":"2014","unstructured":"Shen J, Townsend R, You X, Shen Y, Zhan P, Zhou Z, et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Investig. 2014;34(2):117\u201326. https:\/\/doi.org\/10.1007\/s40261-013-0153-2.","journal-title":"Clin Drug Investig"},{"key":"790_CR34","unstructured":"European Medicines Agency. Idefirix (imlifidase): summary of product characteristics. Amsterdam: European Medicines Agency; 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idefirix-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"issue":"5","key":"790_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/FTD.0000000000000179","volume":"37","author":"GN de Graav","year":"2015","unstructured":"de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA. Therapeutic drug monitoring of belatacept in kidney transplantation. Ther Drug Monit. 2015;37(5):560\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000179.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"790_CR36","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/biomedicines11112955","volume":"11","author":"S Chhun","year":"2023","unstructured":"Chhun S, Trauchessec M, Melicine S, Nicolas F, Miele A, Lukic S, et al. A validated LC-MS\/MS method for performing belatacept drug monitoring in renal transplantation. Biomedicines. 2023;11(11):2955. https:\/\/doi.org\/10.3390\/biomedicines11112955.","journal-title":"Biomedicines."},{"issue":"8","key":"790_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70172","volume":"39","author":"A Pyatt","year":"2025","unstructured":"Pyatt A, McGowan M, Tanaka R, Miyagawa B, Mizuno T, Shields AR, et al. Belatacept pharmacokinetic analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to clinical outcomes and compared with reported BENEFIT and BENEFIT-EXT pharmacokinetic analysis. Clin Transplant. 2025;39(8):e70172. https:\/\/doi.org\/10.1111\/ctr.70172.","journal-title":"Clin Transplant"},{"issue":"4","key":"790_CR38","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/ajt.15236","volume":"19","author":"A Moudgil","year":"2019","unstructured":"Moudgil A, Dharnidharka VR, Feig DI, Warshaw BL, Perera V, Murthy B, et al. Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. Am J Transplant. 2019;19(4):1218\u201323. https:\/\/doi.org\/10.1111\/ajt.15236.","journal-title":"Am J Transplant"},{"issue":"6","key":"790_CR39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/ajt.17005","volume":"22","author":"T de Nattes","year":"2022","unstructured":"de Nattes T, Lebourg L, Etienne I, Laurent C, Lemoine M, Dumont A, et al. CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes. Am J Transplant. 2022;22(6):1691\u20138. https:\/\/doi.org\/10.1111\/ajt.17005.","journal-title":"Am J Transplant"},{"issue":"9","key":"790_CR40","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381\u20139. https:\/\/doi.org\/10.1111\/ajt.14228.","journal-title":"Am J Transplant"},{"key":"790_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839380","volume":"13","author":"L Cabezas","year":"2022","unstructured":"Cabezas L, Jouve T, Malvezzi P, Janbon B, Giovannini D, Rostaing L, et al. Tocilizumab and active antibody-mediated rejection in kidney transplantation: a literature review. Front Immunol. 2022;13:839380. https:\/\/doi.org\/10.3389\/fimmu.2022.839380.","journal-title":"Front Immunol"},{"issue":"1","key":"790_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/jcm11010091","volume":"11","author":"A Truffot","year":"2021","unstructured":"Truffot A, Jouve T, Noble J, Bardy B, Malvezzi P, Rostaing L, et al. Tocilizumab trough levels variability in kidney-transplant candidates undergoing desensitization. J Clin Med. 2021;11(1):91. https:\/\/doi.org\/10.3390\/jcm11010091.","journal-title":"J Clin Med"},{"issue":"1","key":"790_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08020-0","volume":"25","author":"L Streichart","year":"2024","unstructured":"Streichart L, Felldin M, Ekberg J, Mj\u00f6rnstedt L, Lindn\u00e9r P, Lennerling A, et al. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study). Trials. 2024;25(1):213. https:\/\/doi.org\/10.1186\/s13063-024-08020-0.","journal-title":"Trials"},{"issue":"10","key":"790_CR44","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyd\u00e9n G. Pharmacodynamics of Rituximab in kidney allotransplantation. Am J Transplant. 2006;6(10):2418\u201328. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01497.x.","journal-title":"Am J Transplant"},{"issue":"2","key":"790_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ame2.12064","volume":"2","author":"K Chauhan","year":"2019","unstructured":"Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Anim Model Exp Med. 2019;2(2):76\u201382. https:\/\/doi.org\/10.1002\/ame2.12064.","journal-title":"Anim Model Exp Med"},{"issue":"9","key":"790_CR46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9(9):995\u20131001. https:\/\/doi.org\/10.1023\/A:1008416911099.","journal-title":"Ann Oncol"},{"issue":"5","key":"790_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, et al. Japanese multicenter phase II and pharmacokinetic study of Rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15(5):821\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdh176.","journal-title":"Ann Oncol"},{"issue":"6","key":"790_CR48","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","volume":"4","author":"YT Becker","year":"2004","unstructured":"Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6):996\u20131001. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00454.x.","journal-title":"Am J Transplant"},{"issue":"2","key":"790_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ajt.13052","volume":"15","author":"MWF van den Hoogen","year":"2015","unstructured":"van den Hoogen MWF, Kamburova EG, Baas MC, Steenbergen EJ, Florquin S, Koenen MHJP, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant. 2015;15(2):407\u201316. https:\/\/doi.org\/10.1111\/ajt.13052.","journal-title":"Am J Transplant"},{"issue":"12","key":"790_CR50","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/iju.14387","volume":"27","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T. Editorial comment to low-dose Rituximab induction therapy is effective in immunological high-risk renal transplantation without increasing cytomegalovirus infection. Int J Urol. 2020;27(12):1142\u20133. https:\/\/doi.org\/10.1111\/iju.14387.","journal-title":"Int J Urol"},{"issue":"12","key":"790_CR51","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1080\/10428190802475303","volume":"49","author":"T Elter","year":"2008","unstructured":"Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. Pharmacokinetics of Alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008;49(12):2256\u201362. https:\/\/doi.org\/10.1080\/10428190802475303.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"790_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2022.100686","volume":"36","author":"CA Chukwu","year":"2022","unstructured":"Chukwu CA, Spiers HVM, Middleton R, Kalra PA, Asderakis A, Rao A, et al. Alemtuzumab in renal transplantation: reviews of literature and usage in the United Kingdom. Transplant Rev. 2022;36(2):100686. https:\/\/doi.org\/10.1016\/j.trre.2022.100686.","journal-title":"Transplant Rev"},{"issue":"3","key":"790_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cpt.3714","volume":"118","author":"LK van Vugt","year":"2025","unstructured":"van Vugt LK, Zwart TC, Bezstarosti S, Heidt S, Reinders MEJ, Hesselink DA, et al. Alemtuzumab exposure and T lymphocyte depletion: a population pharmacokinetic-pharmacodynamic model of alemtuzumab induction therapy for kidney transplantation. Clin Pharmacol Ther. 2025;118(3):662\u201372. https:\/\/doi.org\/10.1002\/cpt.3714.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"790_CR54","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","volume":"7","author":"FR Achini-Gutzwiller","year":"2023","unstructured":"Achini-Gutzwiller FR, Schilham MW, von Asmuth EGJ, Jansen-Hoogendijk AM, Jol-van der Zijde CM, van Tol MJD, et al. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood Adv. 2023;7(16):4462\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2022009051.","journal-title":"Blood Adv"},{"issue":"1","key":"790_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2231264","volume":"45","author":"ZC Tang","year":"2023","unstructured":"Tang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. Ren Fail. 2023;45(1):2231264. https:\/\/doi.org\/10.1080\/0886022X.2023.2231264.","journal-title":"Ren Fail"},{"issue":"7","key":"790_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859\u201374. https:\/\/doi.org\/10.1007\/s40262-019-00742-8.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"790_CR57","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","volume":"7","author":"P Gatault","year":"2015","unstructured":"Gatault P, Brachet G, Ternant D, Degenne D, R\u00e9cipon G, Barbet C, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs. 2015;7(6):1205\u201311. https:\/\/doi.org\/10.1080\/19420862.2015.1086049.","journal-title":"MAbs"},{"issue":"2","key":"790_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/ndt\/gfac056","volume":"38","author":"M Ter Avest","year":"2023","unstructured":"Ter Avest M, Bouwmeester RN, Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPWJ, et al. Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrol Dial Transplant. 2023;38(2):362\u201371. https:\/\/doi.org\/10.1093\/ndt\/gfac056.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"790_CR59","doi-asserted-by":"publisher","first-page":"T16","DOI":"10.1016\/j.farma.2023.09.009","volume":"48","author":"AP Parra","year":"2024","unstructured":"Parra AP, Ramos N, Perurena-Prieto J, Manrique-Rodr\u00edguez S, Climente M, Quintanilla LG, et al. [Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy. Farm Hosp. 2024;48(1):T16-22. https:\/\/doi.org\/10.1016\/j.farma.2023.09.009.","journal-title":"Farm Hosp"},{"issue":"11","key":"790_CR60","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2023012267","volume":"8","author":"S Chonat","year":"2024","unstructured":"Chonat S, Kulagin A, Maschan A, Bartels M, Buechner J, Punzalan R, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024;8(11):2813\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2023012267.","journal-title":"Blood Adv"},{"issue":"6","key":"790_CR61","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-025-07113-5","volume":"41","author":"SMM Nunez","year":"2026","unstructured":"Nunez SMM, Brokenshire S, Srivaths P, Angelo J, Shah S, Michael M. Evaluation of ravulizumab trough levels in pediatric complement-mediated hemolytic uremic syndrome in remission. Pediatr Nephrol. 2026;41(6):1753\u201360. https:\/\/doi.org\/10.1007\/s00467-025-07113-5.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"790_CR62","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/ajt.16926","volume":"22","author":"AA Vo","year":"2022","unstructured":"Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, et al. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transplant. 2022;22(4):1133\u201344. https:\/\/doi.org\/10.1111\/ajt.16926.","journal-title":"Am J Transplant"},{"issue":"Suppl. 3","key":"790_CR63","first-page":"D97","volume":"19","author":"SC Jordan","year":"2019","unstructured":"Jordan SC, Vescio R, Toyoda M, Ammerman N, Huang E, Peng A, et al. Daratumumab for treatment of antibody-mediated rejection in a kidney transplant recipient [abstract]. Am J Transplant. 2019;19(Suppl. 3):D97.","journal-title":"Am J Transplant"},{"issue":"13","key":"790_CR64","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1506348.","journal-title":"N Engl J Med"},{"issue":"6","key":"790_CR65","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","volume":"7","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7(6):e447\u201355. https:\/\/doi.org\/10.1016\/S2352-3026(20)30081-8.","journal-title":"Lancet Haematol."},{"issue":"8","key":"790_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","volume":"56","author":"PL Clemens","year":"2017","unstructured":"Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(8):915\u201324. https:\/\/doi.org\/10.1007\/s40262-016-0477-1.","journal-title":"Clin Pharmacokinet"},{"key":"790_CR67","unstructured":"US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s): daratumumab (Darzalex\u00ae). Silver Spring (MD): Center for Drug Evaluation and Research (CDER), US Food and Drug Administration; 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761036Orig1s000ClinPharmR.pdf. [Accessed 3 Jun 2026]."},{"key":"790_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11771","volume":"36","author":"D Zhao","year":"2023","unstructured":"Zhao D, Guo Z, Zhao G, Sa R, Zhu L, Chen G. A novel daratumumab-based regimen for desensitization in highly HLA-presensitized patients awaiting kidney transplantation. Transpl Int. 2023;36:11771. https:\/\/doi.org\/10.3389\/ti.2023.11771.","journal-title":"Transpl Int"},{"key":"790_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382977","volume":"15","author":"Z Chen","year":"2024","unstructured":"Chen Z, Xu Q, Shou Z. Application of CD38 monoclonal antibody in kidney disease. Front Immunol. 2024;15:1382977. https:\/\/doi.org\/10.3389\/fimmu.2024.1382977.","journal-title":"Front Immunol"},{"issue":"9","key":"790_CR70","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.1002\/ajh.27001","volume":"98","author":"E Kastritis","year":"2023","unstructured":"Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, et al. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: the DARE study. Am J Hematol. 2023;98(9):E226\u20139. https:\/\/doi.org\/10.1002\/ajh.27001.","journal-title":"Am J Hematol"},{"issue":"6","key":"790_CR71","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","volume":"62","author":"K Kim","year":"2023","unstructured":"Kim K, Phelps MA. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin Pharmacokinet. 2023;62(6):789\u2013806. https:\/\/doi.org\/10.1007\/s40262-023-01240-8.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"790_CR72","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","volume":"86","author":"B H\u00f6cker","year":"2008","unstructured":"H\u00f6cker B, Kovarik JM, Daniel V, Opelz G, Fehrenbach H, Holder M, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation. 2008;86(9):1234\u201340. https:\/\/doi.org\/10.1097\/TP.0b013e318188ae18.","journal-title":"Transplantation"},{"issue":"11","key":"790_CR73","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/ajt.14733","volume":"18","author":"T Lorant","year":"2018","unstructured":"Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, J\u00e4rnum S, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018;18(11):2752\u201362. https:\/\/doi.org\/10.1111\/ajt.14733.","journal-title":"Am J Transplant"},{"key":"790_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2022.951360","volume":"1","author":"M Durlik","year":"2022","unstructured":"Durlik M. New approach to desensitization in solid organ transplantation-imlifidase. Front Transplant. 2022;1:951360. https:\/\/doi.org\/10.3389\/frtra.2022.951360.","journal-title":"Front Transplant"},{"issue":"2","key":"790_CR75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14712598.2021.1850685","volume":"21","author":"BE Lonze","year":"2021","unstructured":"Lonze BE. A review of imlifidase in solid organ transplantation. Expert Opin Biol Ther. 2021;21(2):135\u201343. https:\/\/doi.org\/10.1080\/14712598.2021.1850685.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"790_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/14789450.2015.1050384","volume":"12","author":"P Bults","year":"2015","unstructured":"Bults P, van de Merbel NC, Bischoff R. Quantification of biopharmaceuticals and biomarkers in complex biological matrices: a comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays. Expert Rev Proteomics. 2015;12(4):355\u201374. https:\/\/doi.org\/10.1586\/14789450.2015.1050384.","journal-title":"Expert Rev Proteomics"},{"key":"790_CR77","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clinbiochem.2020.10.007","volume":"87","author":"A Truffot","year":"2020","unstructured":"Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, et al. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem. 2020;87:60\u20136. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.10.007.","journal-title":"Clin Biochem"},{"issue":"5","key":"790_CR78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00216-016-0045-4","volume":"409","author":"JF Jourdil","year":"2017","unstructured":"Jourdil JF, Lebert D, Gautier-Veyret E, Lemaitre F, Bonaz B, Picard G, et al. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? Anal Bioanal Chem. 2017;409(5):1195\u2013205. https:\/\/doi.org\/10.1007\/s00216-016-0045-4.","journal-title":"Anal Bioanal Chem"},{"issue":"16","key":"790_CR79","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.4155\/bio-2018-0091","volume":"10","author":"D Egging","year":"2018","unstructured":"Egging D, Verhagen J, de Laat-Arts K, de Wit B, van Boekel T, Buurman M, et al. Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. Bioanalysis. 2018;10(16):1289\u2013306. https:\/\/doi.org\/10.4155\/bio-2018-0091.","journal-title":"Bioanalysis"},{"issue":"1","key":"790_CR80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/apt.16135","volume":"53","author":"R Nice","year":"2021","unstructured":"Nice R, Chanchlani N, Green H, Bewshea C, Ahmad T, Goodhand JR, et al. Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther. 2021;53(1):128\u201337. https:\/\/doi.org\/10.1111\/apt.16135.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"790_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/FTD.0000000000000580","volume":"41","author":"RA Klaasen","year":"2019","unstructured":"Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, et al. A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients. Ther Drug Monit. 2019;41(1):11\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000580.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"790_CR82","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4155\/bio.12.79","volume":"4","author":"HA Myler","year":"2012","unstructured":"Myler HA, Phillips KR, Dong H, Tabler E, Shaikh M, Coats V, et al. Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix\u00ae, a CTLA-4-Fc fusion protein, in renal and liver transplant patients. Bioanalysis. 2012;4(10):1215\u201326. https:\/\/doi.org\/10.4155\/bio.12.79.","journal-title":"Bioanalysis"},{"issue":"6","key":"790_CR83","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jpha.2022.08.003","volume":"12","author":"T Mochizuki","year":"2022","unstructured":"Mochizuki T, Shibata K, Naito T, Shimoyama K, Ogawa N, Maekawa M, et al. LC-MS\/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification. J Pharm Anal. 2022;12(6):852\u20139. https:\/\/doi.org\/10.1016\/j.jpha.2022.08.003.","journal-title":"J Pharm Anal"},{"issue":"2","key":"790_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2016.1183039","volume":"46","author":"EL Kneepkens","year":"2017","unstructured":"Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol. 2017;46(2):2. https:\/\/doi.org\/10.1080\/03009742.2016.1183039.","journal-title":"Scand J Rheumatol"},{"issue":"1\u20112","key":"790_CR85","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jim.2007.06.011","volume":"325","author":"H Blasco","year":"2007","unstructured":"Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007;325(1\u20112):127\u201339. https:\/\/doi.org\/10.1016\/j.jim.2007.06.011.","journal-title":"J Immunol Methods"},{"key":"790_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1572739","volume":"16","author":"B Eicher","year":"2025","unstructured":"Eicher B, Esslinger C, Hillenbrand M. Quantification of endogenous and therapeutic IgG crossing the kidney barrier from bloodstream to urine. Front Pharmacol. 2025;16:1572739. https:\/\/doi.org\/10.3389\/fphar.2025.1572739.","journal-title":"Front Pharmacol"},{"issue":"12","key":"790_CR87","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2004.04.003","volume":"28","author":"I Jilani","year":"2004","unstructured":"Jilani I, Keating M, Giles FJ, O\u2019Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004;28(12):1255\u201362. https:\/\/doi.org\/10.1016\/j.leukres.2004.04.003.","journal-title":"Leuk Res"},{"issue":"1","key":"790_CR88","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/FTD.0000000000001037","volume":"45","author":"FR Achini-Gutzwiller","year":"2023","unstructured":"Achini-Gutzwiller FR, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Lankester AC, Bredius RGM, van Tol MJD, et al. Development and validation of an efficient and highly sensitive enzyme-linked immunosorbent assay for alemtuzumab quantification in human serum and plasma. Ther Drug Monit. 2023;45(1):79\u201386. https:\/\/doi.org\/10.1097\/FTD.0000000000001037.","journal-title":"Ther Drug Monit"},{"key":"790_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696387","volume":"12","author":"P Singh","year":"2021","unstructured":"Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder. Front Neurol. 2021;12:696387. https:\/\/doi.org\/10.3389\/fneur.2021.696387.","journal-title":"Front Neurol"},{"issue":"23","key":"790_CR90","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2017006866.","journal-title":"Blood Adv"},{"issue":"2","key":"790_CR91","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.transproceed.2005.01.050","volume":"37","author":"M Nojima","year":"2005","unstructured":"Nojima M, Yoshimoto T, Nakao A, Itahana R, Kyo M, Hashimoto M, et al. Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. Transplant Proc. 2005;37(2):875\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2005.01.050.","journal-title":"Transplant Proc"},{"issue":"1","key":"790_CR92","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/phar.2347","volume":"40","author":"JT Podichetty","year":"2020","unstructured":"Podichetty JT, Brinda BJ, Nelson RP, Karr AH, Prasad NK, Quinney S, et al. Pharmacokinetics of basiliximab for the prevention of graft-versus-host disease in patients undergoing hematopoietic cell transplantation with minimal-intensity cyclophosphamide and fludarabine. Pharmacotherapy. 2020;40(1):26\u201332. https:\/\/doi.org\/10.1002\/phar.2347.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"790_CR93","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3324\/haematol.2022.281895","volume":"108","author":"M Bou-Jaoudeh","year":"2023","unstructured":"Bou-Jaoudeh M, Delignat S, Daventure V, Astermark J, L\u00e9vesque H, Dimitrov JD, et al. The IgG-degrading enzyme, imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice. Haematologica. 2023;108(5):1322\u201334. https:\/\/doi.org\/10.3324\/haematol.2022.281895.","journal-title":"Haematologica"},{"key":"790_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchromb.2011.09.030","volume":"883\u2011884","author":"M Rauh","year":"2012","unstructured":"Rauh M. LC\u2013MS\/MS for protein and peptide quantification in clinical chemistry. J Chromatogr B. 2012;883\u2011884:59\u201367. https:\/\/doi.org\/10.1016\/j.jchromb.2011.09.030.","journal-title":"J Chromatogr B"},{"issue":"5","key":"790_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26051383","volume":"26","author":"A Millet","year":"2021","unstructured":"Millet A, Khoudour N, Lebert D, Machon C, Terrier B, Blanchet B, et al. Development, validation, and comparison of two mass spectrometry methods (LC-MS\/HRMS and LC-MS\/MS) for the quantification of rituximab in human plasma. Molecules. 2021;26(5):1\u201317. https:\/\/doi.org\/10.3390\/molecules26051383.","journal-title":"Molecules"},{"issue":"10","key":"790_CR96","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4155\/bio-2018-0027","volume":"10","author":"J Vialaret","year":"2018","unstructured":"Vialaret J, Broutin S, Pugnier C, Santel\u00e9 S, Jaffuel A, Barnes A, et al. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? Bioanalysis. 2018;10(10):723\u201335. https:\/\/doi.org\/10.4155\/bio-2018-0027.","journal-title":"Bioanalysis"},{"key":"790_CR97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jchromb.2016.04.038","volume":"1023\u20131024","author":"N Iwamoto","year":"2016","unstructured":"Iwamoto N, Shimada T, Terakado H, Hamada A. Validated LC-MS\/MS analysis of immune checkpoint inhibitor nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1023\u20131024:9\u201316. https:\/\/doi.org\/10.1016\/j.jchromb.2016.04.038.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"790_CR98","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/FTD.0000000000000514","volume":"40","author":"JF Jourdil","year":"2018","unstructured":"Jourdil JF, N\u00e9moz B, Gautier-Veyret E, Romero C, Stanke-Labesque F. Simultaneous quantification of Adalimumab and Infliximab in human plasma by liquid chromatography\u2013tandem mass spectrometry. Ther Drug Monit. 2018;40(4):417\u201328. https:\/\/doi.org\/10.1097\/FTD.0000000000000514.","journal-title":"Ther Drug Monit"},{"issue":"xxxx","key":"790_CR99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.aca.2019.03.033","volume":"1067","author":"T Willeman","year":"2019","unstructured":"Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque F. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn\u2019s disease. Anal Chim Acta. 2019;1067(xxxx):63\u201370. https:\/\/doi.org\/10.1016\/j.aca.2019.03.033.","journal-title":"Anal Chim Acta"},{"key":"790_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2012.02.021","volume":"893-894","author":"KJ Bronsema","year":"2012","unstructured":"Bronsema KJ, Bischoff R, Van de Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893\u2013894:1\u201314. https:\/\/doi.org\/10.1016\/j.jchromb.2012.02.021.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"790_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2022.12.014","volume":"113","author":"A Truffot","year":"2023","unstructured":"Truffot A, Jourdil JF, Veyret-Gautier E, Noble J, Jouve T, Malvezzi P, et al. Quantification of Belatacept by liquid chromatography-tandem mass spectrometry in human plasma: application to a pharmacokinetic study in renal transplant recipients. Clin Biochem. 2023;113:17\u201320. https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.12.014.","journal-title":"Clin Biochem"},{"key":"790_CR102","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jmsacl.2023.11.002","volume":"30","author":"CM Shuford","year":"2023","unstructured":"Shuford CM, Grant RP. Cheaper, faster, simpler trypsin digestion for high-throughput targeted protein quantification. J Mass Spectrom Adv Clin Lab. 2023;30:74\u201382. https:\/\/doi.org\/10.1016\/j.jmsacl.2023.11.002.","journal-title":"J Mass Spectrom Adv Clin Lab"},{"issue":"8","key":"790_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080796","volume":"14","author":"C Marin","year":"2021","unstructured":"Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, et al. Cross-validation of a multiplex lc-ms\/ms method for assaying mabs plasma levels in patients with cancer: a GPCO-UNICANCER study. Pharmaceuticals Basel. 2021;14(8):796. https:\/\/doi.org\/10.3390\/ph14080796.","journal-title":"Pharmaceuticals Basel"},{"key":"790_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2021.339231","volume":"1189","author":"HH Chiu","year":"2022","unstructured":"Chiu HH, Tsai YJ, Lo C, Liao HW, Lin CH, Tang SC, et al. Development of an LC-MS\/MS method to simultaneously quantify therapeutic mAbs and estimate hematocrit values in dried blood spot samples. Anal Chim Acta. 2022;1189:339231. https:\/\/doi.org\/10.1016\/j.aca.2021.339231.","journal-title":"Anal Chim Acta"},{"issue":"12","key":"790_CR105","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1021\/acs.analchem.6b00544","volume":"88","author":"JR Mills","year":"2016","unstructured":"Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, et al. Using mass spectrometry to quantify Rituximab and perform individualized immunoglobulin phenotyping in ANCA-associated vasculitis. Anal Chem. 2016;88(12):6317\u201325. https:\/\/doi.org\/10.1021\/acs.analchem.6b00544.","journal-title":"Anal Chem"},{"issue":"26","key":"790_CR106","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1039\/d4ay00404c","volume":"16","author":"G Canil","year":"2024","unstructured":"Canil G, Miolo G, Simula M, Rupolo M, Steffan A, Corona G. Quantitative assessment of Daratumumab in serum via intact light chain measurement using liquid chromatography-high resolution mass spectrometry: a method suitable for therapeutic drug monitoring. Anal Methods. 2024;16(26):4240\u20136. https:\/\/doi.org\/10.1039\/d4ay00404c.","journal-title":"Anal Methods"},{"key":"790_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116627","volume":"255","author":"W Li","year":"2025","unstructured":"Li W, Tian Z, Yu X, Xu H, Huang F, Yu J, et al. Quantification of serum Daratumumab in multiple myeloma patients by LC-MS\/MS, comparison with ELISA. J Pharm Biomed Anal. 2025;255:116627. https:\/\/doi.org\/10.1016\/j.jpba.2024.116627.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"790_CR108","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s13361-016-1566-y","volume":"28","author":"PM Ladwig","year":"2017","unstructured":"Ladwig PM, Barnidge DR, Willrich MAV. Quantification of the IgG2\/4 kappa monoclonal therapeutic Eculizumab from serum using isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry. J Am Soc Mass Spectrom. 2017;28(5):811\u20137. https:\/\/doi.org\/10.1007\/s13361-016-1566-y.","journal-title":"J Am Soc Mass Spectrom"},{"key":"790_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112944","volume":"490","author":"MAV Willrich","year":"2021","unstructured":"Willrich MAV, Ladwig PM, Martinez MA, Sridharan MR, Go RS, Murray DL, et al. Monitoring ravulizumab effect on complement assays. J Immunol Methods. 2021;490:112944. https:\/\/doi.org\/10.1016\/j.jim.2020.112944.","journal-title":"J Immunol Methods"},{"issue":"4","key":"790_CR110","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10157-016-1321-5","volume":"21","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, et al. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Clin Exp Nephrol. 2017;21(4):705\u201313. https:\/\/doi.org\/10.1007\/s10157-016-1321-5.","journal-title":"Clin Exp Nephrol"},{"key":"790_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79:105009. https:\/\/doi.org\/10.1016\/j.msard.2023.105009.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"790_CR112","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00467-022-05652-9","volume":"38","author":"Y Inoki","year":"2023","unstructured":"Inoki Y, Nishi K, Sato M, Ogura M, Kamei K. The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome. Pediatr Nephrol. 2023;38(2):451\u201360. https:\/\/doi.org\/10.1007\/s00467-022-05652-9.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"790_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.757","volume":"9","author":"E Chatelut","year":"2021","unstructured":"Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect. 2021;9(2):e00757. https:\/\/doi.org\/10.1002\/prp2.757.","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"790_CR114","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf044","volume":"7","author":"R Arai","year":"2025","unstructured":"Arai R, Condino A, Abraham BP, Hanauer SB, Navaneethan U, Lum D, et al. Impact of precision-guided dosing on clinical decision-making and health care utilization in inflammatory bowel disease: a retrospective pretest\/posttest real-world study. Crohns Colitis 360. 2025;7(3):otaf044. https:\/\/doi.org\/10.1093\/crocol\/otaf044.","journal-title":"Crohns Colitis 360"},{"issue":"4","key":"790_CR115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/phar.2915","volume":"44","author":"ER Alizadeh","year":"2024","unstructured":"Alizadeh ER, Dervieux T, Vermeire S, Dubinsky M, D\u2019Haens G, Laharie D, et al. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn\u2019s disease initiating infliximab maintenance therapy. Pharmacotherapy. 2024;44(4):331\u201342. https:\/\/doi.org\/10.1002\/phar.2915.","journal-title":"Pharmacotherapy"},{"key":"790_CR116","unstructured":"European Medicines Agency. Orencia: EPAR: product information. Amsterdam: European Medicines Agency; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orencia-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR117","unstructured":"European Medicines Agency. Simulect: summary of product characteristics. Amsterdam: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simulect-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR118","unstructured":"European Medicines Agency. Idefirix: summary of product characteristics. Amsterdam: European Medicines Agency; 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idefirix-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"key":"790_CR119","unstructured":"European Medicines Agency. Darzalex: EPAR: product information. Amsterdam: European Medicines Agency; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf. [Accessed 22 Oct 2025]."},{"issue":"8","key":"790_CR120","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/tri.13954","volume":"34","author":"J M\u00fchlbacher","year":"2021","unstructured":"M\u00fchlbacher J, Sch\u00f6rgenhofer C, Doberer K, D\u00fcrr M, Budde K, Eskandary F, et al. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021;34(8):1542\u201352. https:\/\/doi.org\/10.1111\/tri.13954.","journal-title":"Transpl Int"},{"issue":"1\u20132","key":"790_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2025.2463092","volume":"34","author":"KA Mayer","year":"2025","unstructured":"Mayer KA, Budde K, Schatzl M, Schrezenmeier E, Diebold M, Jilma B, et al. CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation. Expert Opin Investig Drugs. 2025;34(1\u20132):1\u201310. https:\/\/doi.org\/10.1080\/13543784.2025.2463092.","journal-title":"Expert Opin Investig Drugs"},{"key":"790_CR122","doi-asserted-by":"publisher","first-page":"1017872","DOI":"10.3389\/fimmu.2022.1017872","volume":"13","author":"T Chen","year":"2022","unstructured":"Chen T, Li X, Wang J, Wang X, Zhu T, Rong R, et al. Basiliximab for the therapy of acute T cell-mediated rejection in kidney transplant recipient with BK virus infection: a case report. Front Immunol. 2022;13:1017872. https:\/\/doi.org\/10.3389\/fimmu.2022.1017872.","journal-title":"Front Immunol"},{"issue":"1","key":"790_CR123","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-6143.2012.04328.x","volume":"13","author":"MWF van den Hoogen","year":"2013","unstructured":"van den Hoogen MWF, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant. 2013;13(1):192\u20136. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04328.x.","journal-title":"Am J Transplant"},{"issue":"12","key":"790_CR124","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/01.tp.0000295718.55669.3a","volume":"84","author":"MR Clatworthy","year":"2007","unstructured":"Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJE. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplant. 2007;84(12):1563\u20137. https:\/\/doi.org\/10.1097\/01.tp.0000295718.55669.3a.","journal-title":"Transplant"},{"issue":"12","key":"790_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70046","volume":"38","author":"LK van Vugt","year":"2024","unstructured":"van Vugt LK, Tegzess E, van der Zwan M, Clahsen\u2010van Groningen MC, de Winter BCM, Vart P, et al. Multicenter, real\u2010world clinical evaluation of alemtuzumab and anti\u2010thymocyte globulin for severe acute T cell\u2010mediated kidney transplant rejection. Clin Transplant. 2024;38(12):e70046. https:\/\/doi.org\/10.1111\/ctr.70046.","journal-title":"Clin Transplant"},{"issue":"7","key":"790_CR126","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.transproceed.2021.07.005","volume":"53","author":"MGH Betjes","year":"2021","unstructured":"Betjes MGH, Kho MML, Litjens NHR, de Weerd AE, Roodnat JI. Alemtuzumab as second-line treatment for late antibody-mediated rejection of transplanted kidneys. Transplant Proc. 2021;53(7):2206\u201311. https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.005.","journal-title":"Transplant Proc"},{"key":"790_CR127","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DDDT.S10432","volume":"4","author":"G Gupta","year":"2010","unstructured":"Gupta G, Womer KL. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. Drug Des Devel Ther. 2010;4:375\u201382. https:\/\/doi.org\/10.2147\/DDDT.S10432.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"790_CR128","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","volume":"10","author":"F Vincenti","year":"2010","unstructured":"Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept\u2010based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant. 2010;10(3):535\u201346. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.03005.x.","journal-title":"Am J Transplant"},{"issue":"12","key":"790_CR129","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1681\/ASN.2021050628","volume":"32","author":"K Budde","year":"2021","unstructured":"Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, et al. Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial. J Am Soc Nephrol. 2021;32(12):3252\u201364. https:\/\/doi.org\/10.1681\/ASN.2021050628.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"790_CR130","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","volume":"19","author":"G Divard","year":"2024","unstructured":"Divard G, Aubert O, Debiais-Deschamp C, Raynaud M, Goutaudier V, Sablik M, et al. Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients. Clin J Am Soc Nephrol. 2024;19(5):628\u201337. https:\/\/doi.org\/10.2215\/CJN.0000000000000411.","journal-title":"Clin J Am Soc Nephrol"},{"key":"790_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13544","volume":"37","author":"D Bertrand","year":"2024","unstructured":"Bertrand D, Chavarot N, Olagne J, Greze C, Gatault P, Danthu C, et al. Biopsy-proven T-cell mediated rejection after belatacept rescue conversion: a multicenter retrospective study. Transpl Int. 2024;37:13544. https:\/\/doi.org\/10.3389\/ti.2024.13544.","journal-title":"Transpl Int"},{"key":"790_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10681","volume":"35","author":"C Uro-Coste","year":"2022","unstructured":"Uro-Coste C, Atenza A, Heng AE, Rouzaire PO, Garrouste C. Abatacept rescue therapy in kidney transplant recipients: a case series of five patients. Transpl Int. 2022;35:10681. https:\/\/doi.org\/10.3389\/ti.2022.10681.","journal-title":"Transpl Int"},{"key":"790_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.790547","volume":"8","author":"J Noble","year":"2021","unstructured":"Noble J, Giovannini D, Laamech R, Imerzoukene F, Janbon B, Marchesi L, et al. Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring. Front Med. 2021;8:790547. https:\/\/doi.org\/10.3389\/fmed.2021.790547.","journal-title":"Front Med"},{"issue":"3","key":"790_CR134","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1111\/ctr.12102","volume":"27","author":"ANR Barnett","year":"2013","unstructured":"Barnett ANR, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant. 2013;27(3):E216\u201329. https:\/\/doi.org\/10.1111\/ctr.12102.","journal-title":"Clin Transplant"},{"issue":"1","key":"790_CR135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.transproceed.2021.09.063","volume":"54","author":"CC Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez CC, L\u00f3pez-Jim\u00e9nez V, V\u00e1zquez-S\u00e1nchez T, V\u00e1zquez-S\u00e1nchez E, Cabello M, Hern\u00e1ndez-Marrero D. Efficacy and safety of eculizumab in kidney transplant patients with primary atypical hemolytic-uremic syndrome. Transplant Proc. 2022;54(1):25\u20136. https:\/\/doi.org\/10.1016\/j.transproceed.2021.09.063.","journal-title":"Transplant Proc"},{"key":"790_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01847-0","volume":"21","author":"S Kant","year":"2020","unstructured":"Kant S, Bhalla A, Alasfar S, Alachkar N. Ten-year outcome of eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome: a single center experience. BMC Nephrol. 2020;21:189. https:\/\/doi.org\/10.1186\/s12882-020-01847-0.","journal-title":"BMC Nephrol"},{"issue":"11","key":"790_CR137","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","volume":"103","author":"EK Tan","year":"2019","unstructured":"Tan EK, Bentall AJ, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. Transplantation. 2019;103(11):2397\u2013404. https:\/\/doi.org\/10.1097\/TP.0000000000002639.","journal-title":"Transplantation"},{"issue":"2","key":"790_CR138","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001289","volume":"8","author":"T Schmidt","year":"2022","unstructured":"Schmidt T, G\u00f6del M, Mahmud M, Fischer L, Huber TB, Kluger MA, et al. Ravulizumab in preemptive living donor kidney transplantation in hereditary atypical hemolytic uremic syndrome. Transplant Direct. 2022;8(2):e1289. https:\/\/doi.org\/10.1097\/TXD.0000000000001289.","journal-title":"Transplant Direct"},{"key":"790_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10846","volume":"35","author":"U Jehn","year":"2022","unstructured":"Jehn U, Altuner U, Pavenst\u00e4dt H, Reuter S. First report on successful conversion of long-term treatment of recurrent atypical hemolytic uremic syndrome with eculizumab to ravulizumab in a renal transplant patient. Transpl Int. 2022;35:10846. https:\/\/doi.org\/10.3389\/ti.2022.10846.","journal-title":"Transpl Int"},{"issue":"10","key":"790_CR140","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1016\/j.transproceed.2020.02.166","volume":"52","author":"SD Hwang","year":"2020","unstructured":"Hwang SD, Lee JH, Kim K, Lee SW, Song JH. Effect of rituximab used as induction in patients with ABO mismatch kidney transplant: a systematic review and meta-analysis. Transplant Proc. 2020;52(10):3125\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2020.02.166.","journal-title":"Transplant Proc"},{"issue":"10","key":"790_CR141","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024853","volume":"100","author":"HR Lee","year":"2021","unstructured":"Lee HR, Kim K, Lee SW, Song JH, Lee JH, Hwang SD. Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation. Medicine (Baltimore). 2021;100(10):e24853. https:\/\/doi.org\/10.1097\/MD.0000000000024853.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"790_CR142","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s11255-013-0599-4","volume":"46","author":"Y-G Zhao","year":"2014","unstructured":"Zhao Y-G, Shi B-Y, Qian Y-Y, Bai H-W, Xiao L, He X-Y. Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis. Int Urol Nephrol. 2014;46(6):1225\u201330. https:\/\/doi.org\/10.1007\/s11255-013-0599-4.","journal-title":"Int Urol Nephrol"},{"key":"790_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04543-z","volume":"26","author":"B Yilmaz","year":"2025","unstructured":"Yilmaz B, Uslu A, Ta\u015fli F, Durusoy R, Do\u011fan SM, Okut G, et al. Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes. BMC Nephrol. 2025;26:600. https:\/\/doi.org\/10.1186\/s12882-025-04543-z.","journal-title":"BMC Nephrol"},{"issue":"7","key":"790_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15383","volume":"38","author":"F Halleck","year":"2024","unstructured":"Halleck F, B\u00f6hmig GA, Couzi L, Rostaing L, Einecke G, Lefaucheur C, et al. A randomized trial comparing imlifidase to plasmapheresis in kidney transplant recipients with antibody-mediated rejection. Clin Transplant. 2024;38(7):e15383. https:\/\/doi.org\/10.1111\/ctr.15383.","journal-title":"Clin Transplant"},{"issue":"3","key":"790_CR145","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/ajt.16828","volume":"22","author":"E Huang","year":"2022","unstructured":"Huang E, Maldonado AQ, Kjellman C, Jordan SC. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant. 2022;22(3):691\u20137. https:\/\/doi.org\/10.1111\/ajt.16828.","journal-title":"Am J Transplant"},{"issue":"10","key":"790_CR146","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/j.ekir.2024.07.024","volume":"9","author":"N Kamar","year":"2024","unstructured":"Kamar N, Bertrand D, Caillard S, Pievani D, Apithy MJ, Congy-Jolivet N, et al. Imlifidase in highly sensitized kidney transplant recipients with a positive crossmatch against a deceased donor. Kidney Int Rep. 2024;9(10):2927\u201336. https:\/\/doi.org\/10.1016\/j.ekir.2024.07.024.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"790_CR147","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae033","volume":"17","author":"M Kanbay","year":"2024","unstructured":"Kanbay M, Copur S, Guldan M, Topcu AU, Ozbek L, Hasbal B, et al. Imlifidase in kidney transplantation. Clin Kidney J. 2024;17(3):sfae033. https:\/\/doi.org\/10.1093\/ckj\/sfae033.","journal-title":"Clin Kidney J"},{"issue":"11","key":"790_CR148","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.ekir.2024.08.020","volume":"9","author":"C Pilon","year":"2024","unstructured":"Pilon C, Joher N, Usureau C, Boutin E, Boueilh A, Taupin JL, et al. Open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation. Kidney Int Rep. 2024;9(11):3250\u201364. https:\/\/doi.org\/10.1016\/j.ekir.2024.08.020.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"790_CR149","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajt.2024.08.004","volume":"25","author":"A Torija","year":"2025","unstructured":"Torija A, Matignon M, Vincenti F, Casanova-Ferrer F, Pilon C, Tambur AR, et al. Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates. Am J Transplant. 2025;25(1):88\u2013101. https:\/\/doi.org\/10.1016\/j.ajt.2024.08.004.","journal-title":"Am J Transplant"},{"issue":"2","key":"790_CR150","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40620-024-02182-5","volume":"38","author":"J Oll\u00e9","year":"2025","unstructured":"Oll\u00e9 J, Larque AB, de Larrea CF, Diekmann F, Cucchiari D. Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report. J Nephrol. 2025;38(2):739\u201344. https:\/\/doi.org\/10.1007\/s40620-024-02182-5.","journal-title":"J Nephrol"},{"issue":"3","key":"790_CR151","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000503951","volume":"9","author":"D Spica","year":"2019","unstructured":"Spica D, Junker T, Dickenmann M, Schaub S, Steiger J, R\u00fcfli T, et al. Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation. Case Rep Nephrol Dial. 2019;9(3):149\u201357. https:\/\/doi.org\/10.1159\/000503951.","journal-title":"Case Rep Nephrol Dial"},{"issue":"3","key":"790_CR152","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/ASN.2020071106","volume":"32","author":"K Doberer","year":"2021","unstructured":"Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32(3):708\u201322. https:\/\/doi.org\/10.1681\/ASN.2020071106.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"790_CR153","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","volume":"391","author":"KA Mayer","year":"2024","unstructured":"Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med. 2024;391(2):122\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2400763.","journal-title":"N Engl J Med"},{"issue":"5","key":"790_CR154","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","volume":"31","author":"M Diebold","year":"2025","unstructured":"Diebold M, Gauthier PT, Mayer KA, Mackova M, Hinze C, Chang J, et al. Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies. Nat Med. 2025;31(5):1668\u201376. https:\/\/doi.org\/10.1038\/s41591-025-03653-3.","journal-title":"Nat Med"},{"issue":"2","key":"790_CR155","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1056\/NEJMe2407009","volume":"391","author":"JR Ingelfinger","year":"2024","unstructured":"Ingelfinger JR, Williams WW. Felzartamab and antibody-mediated rejection in kidney transplants: hope at last? N Engl J Med. 2024;391(2):180\u20131. https:\/\/doi.org\/10.1056\/NEJMe2407009.","journal-title":"N Engl J Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00790-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00790-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:37:59Z","timestamp":1783330679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00790-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":155,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00790-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"25 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Capucine Arriv\u00e9, Marie Hotot, Jean-Fran\u00e7ois Jourdil, and Fran\u00e7oise Stanke-Labesque have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"FSL had the idea for the article, MH, CA, JFJ, and FSL performed the literature search and data analysis, and all authors drafted and\/or critically revised the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}